{Reference Type}: Journal Article
{Title}: Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions.
{Author}: Huang C;Li X;Li H;Chen R;Li Z;Li D;Xu X;Zhang G;Qin L;Li B;Chu XM;
{Journal}: J Transl Med
{Volume}: 22
{Issue}: 1
{Year}: 2024 May 8
{Factor}: 8.44
{DOI}: 10.1186/s12967-024-05232-5
{Abstract}: Doxorubicin (DOX) is a broad-spectrum and highly efficient anticancer agent, but its clinical implication is limited by lethal cardiotoxicity. Growing evidences have shown that alterations in intestinal microbial composition and function, namely dysbiosis, are closely linked to the progression of DOX-induced cardiotoxicity (DIC) through regulating the gut-microbiota-heart (GMH) axis. The role of gut microbiota and its metabolites in DIC, however, is largely unelucidated. Our review will focus on the potential mechanism between gut microbiota dysbiosis and DIC, so as to provide novel insights into the pathophysiology of DIC. Furthermore, we summarize the underlying interventions of microbial-targeted therapeutics in DIC, encompassing dietary interventions, fecal microbiota transplantation (FMT), probiotics, antibiotics, and natural phytochemicals. Given the emergence of microbial investigation in DIC, finally we aim to point out a novel direction for future research and clinical intervention of DIC, which may be helpful for the DIC patients.